One-year change in glycated hemoglobin A1c (HbA1c), weight and hypoglycemia incidence, stratified by oral antihyperglycemic agent (OHA) therapy cohort and medication possession ratio (MPR) category
| Regimen | N | One-year HbA1c change (%), mean (95% CI) | One-year HbA1c change (mmol/mol), mean (95% CI) | One-year weight change (kg), mean (95% CI) | Hypoglycemia event rate, n (per 1000 patient-years) |
| OHA monotherapy | 23 925 | −0.8 (−0.9 to −0.8) | −8.7 (−9.8 to −8.7) | −2.5 (−2.6 to −2.3) | 189 (7.9) |
| MPR<80% | 4401 | −0.55 (−0.61 to −0.49) | −6.0 (−6.7 to −5.4) | −1.64 (−1.94 to −1.34) | 29 (6.6) |
| MPR≥80% | 19 524 | −0.90 (−0.93 to −0.87) | −9.8 (−10.2 to −9.5) | −2.65 (−2.80 to −2.50) | 160 (8.2) |
| Difference* | −0.35 (−0.41 to −0.28); p<0.001 | −3.8 (−4.5 to −3.1); p<0.001 | −1.01 (−1.34 to −0.67); p<0.001 | 131 (RR 1.24; p=0.303) | |
| OHA dual therapy | 8406 | −0.9 (−1.0 to −0.9) | −9.8 (−10.9 to −9.8) | 0.6 (0.4 to 0.8) | 152 (18.1) |
| MPR<80% | 1610 | −0.69 (−0.79 to −0.58) | −7.5 (−8.6 to −6.3) | 0.31 (−0.22 to 0.83) | 27 (16.8) |
| MPR≥80% | 6796 | −0.97 (−1.02 to −0.92) | −10.6 (−11.1 to −10.1) | 0.67 (0.46 to 0.88) | 125 (18.4) |
| Difference* | −0.28 (−0.40 to −0.17); p<0.001 | −3.1 (−4.4 to −1.9); p<0.001 | 0.36 (−0.20 to 0.93); p=0.210 | 98 (RR 1.10; p=0.757) | |
| OHA triple therapy | 1518 | −1.0 (−1.1 to −0.9) | −10.9 (−12.0 to −9.8) | 0.5 (0.0 to 0.9) | 58 (38.2) |
| MPR<80% | 291 | −0.49 (−0.74 to −0.25) | −5.4 (−8.1 to −2.7) | 0.26 (−0.65 to 1.17) | 6 (20.6) |
| MPR≥80% | 1227 | −1.14 (−1.25 to −1.04) | −12.5 (−13.7 to −11.4) | 0.50 (0.03 to 0.97) | 52 (42.4) |
| Difference* | −0.65 (−0.92 to −0.38); p<0.001 | −7.1 (−10.1 to −4.2); p<0.001 | 0.24 (0.79 to 1.27); p=0.642 | 46 (RR 2.06; p=0.096) |
*Difference relates to MPR ≥80% versus MPR <80%.
RR, rate ratio.